Home > Resources > Whitepapers > An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry

An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry

Since 1999, the quantity of prescription opioids sold in the United States has nearly quadrupled, resulting in an average of 650,000 opioid prescriptions dispensed daily. Deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have also quadrupled, causing more than 165,000 deaths in the U.S. within a 15-year time period (1999-2014). Additionally, an estimated 1.9 million people in the United States suffer from substance use disorders related to prescription opioid pain medicines.1 How much is the abuse epidemic costing the nation? It has been established that the health and social costs related to prescription opioid abuse total more than $55 billion each year, including $20 billion in emergency room and inpatient care for opioid poisonings.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Bob Martin (UK) Ltd

Bob Martin is a family-run pet care business based in Yatton, Somerset. The company was founded in 1892 by Bob Martin, who created a range of vitamin supplements to improve dog coat condition. Today, the company produces a range of pet medicines, food, grooming, hygiene and accessory products as well as still producing vitamin supplements for pets. It has offices in the UK, Germany, France, Italy, Spain and South Africa and is still owned and run by the Martin family.

OTHER WHITEPAPERS
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More
news image

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More
news image

Utilizing Multi-parameter Epitope Binning to Understand aTherapeutic Antibody’s Mechanism of Action

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

Read More
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
news image

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Read More
news image

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

Utilizing Multi-parameter Epitope Binning to Understand aTherapeutic Antibody’s Mechanism of Action

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

Read More

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Read More

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More
More Whitepapers

Spotlight

Bob Martin (UK) Ltd

Bob Martin is a family-run pet care business based in Yatton, Somerset. The company was founded in 1892 by Bob Martin, who created a range of vitamin supplements to improve dog coat condition. Today, the company produces a range of pet medicines, food, grooming, hygiene and accessory products as well as still producing vitamin supplements for pets. It has offices in the UK, Germany, France, Italy, Spain and South Africa and is still owned and run by the Martin family.

Events

National Medtech & Biotech Summit 2024

Conference